Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

Study shows the repeated long-term, as-needed use of STS101 for the acute treatment of a migraine attack demonstrated a favorable safety profile and was well tolerated. Exploratory Efficacy Endpoints showed that STS101provided rapid freedom from pain (37% of attacks), and rapid freedom from most bothersome symptoms (54% of attacks) at 2 hours and sustained treatment benefits over 48 hours after dosing.

Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs

DURHAM, N.C. , June 13, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd.

Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting

Oral Presentation: Sustained Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase­3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study Oral Presentation: Sustained Efficacy of STS101 DHE Nasal Powder for the Acute Treatment of Migraine: Results from the Phase­3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study

Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 65th Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., May 18, 2023 (GLOBE NEWSWIRE) --  Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company today announced that its 505(b)(2) new drug application (NDA) for STS101, a novel and investigational therapeutic product candidate for the acute treatment of migraine, has been accepted for review by the FDA.

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Satsuma Pharmaceuticals, Inc. (“Satsuma”) (NasdaqGM: STSA) to Shin Nippon Biomedical Laboratories, Ltd. Under the terms of the proposed transaction, shareholders of Satsuma will receive $0.91 in cash, plus one non-tradeable contingent value right (“CVR”) of up to $5.77 per share, for each share of Satsuma that.

SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Satsuma Pharmaceuticals, Inc. - STSA

MILWAUKEE , May 1, 2023 /PRNewswire/ -- Ademi LLP is investigating Satsuma (NASDAQ: STSA) for possible breaches of fiduciary duty and other violations of law in its transaction with Shin Nippon.  Click here to learn how to join the action https://www.ademilaw.com/case/satsuma-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin Nippon

SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology's (AAN) 75th Annual Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format in Boston, Massachusetts from Saturday, April 22 to Thursday, April 27, 2023. Full abstracts are now available on the AAN website.

Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) to Shin Nippon Biomedical Laboratories, Ltd. for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right of up to $5.77 per share is fair to Satsuma shareholders.

STSA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Satsuma Pharmaceuticals, Inc. Is Fair to Shareholders

Satsuma Pharmaceuticals (NASDAQ: STSA ) stock is taking off on Monday after revealing an acquisition deal with Shin Nippon Biomedical Laboratories. That deal has Shin Nippon Biomedical Laboratories agreeing to acquire STSA stock for 91 cents per share.

Why Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?

Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share Satsuma stockholders to also receive non-tradeable CVR of up to $5.77 per share With the goal of maximizing value for stockholders, Satsuma's Board has carefully considered strategic options for Satsuma and STS101 and fully supports this transaction with SNBL SOUTH SAN FRANCISCO, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (“Satsuma”) (Nasdaq: STSA) today announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd.

SNBL to Acquire Satsuma Pharmaceuticals

- Announced topline results from STS101 SUMMIT Phase 3 efficacy trial that the company believes demonstrate STS101 provides differentiated, robust and sustained anti-migraine effects -

Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, President and Chief Executive Officer, will deliver a company presentation during the SVB Securities Global Biopharma Conference, which is being held virtually February 14-16. Mr. Kollins will also host virtual one-on-one meetings with investors.

Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today provided an update on its STS101 development program and corporate update.

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update

Charah Solutions Inc

Canoo

Heliogen

Porch Group

TFF Pharmaceuticals

Venus Concept

7 penny stock picks from insiders in November 2022 The post Best Penny Stocks To Buy Now? 7 Insider Picks In November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 7 Insider Picks In November

Company to comment on STS101 regulatory pathway and potential implications of SUMMIT trial results Company to comment on STS101 regulatory pathway and potential implications of SUMMIT trial results

Satsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

AirSculpt Technologies

Ardelyx

Cronos Group

Nerdy

Weightwatchers International Inc.

Penny stocks to buy according to insiders in November 2022. The post Penny Stocks To Buy: 7 Insider Picks For November 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 7 Insider Picks For November 2022

The focus in the world of drugmakers is on Satsuma Pharmaceuticals (NASDAQ: STSA ) right now, but not in a good way. Specifically, the company's proposed treatment for migraine headaches didn't meet its “primary endpoints,” as they say.

Why Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today?

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported topline results from the STS101 SUMMIT Phase 3 efficacy trial.

Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine

- On track to report topline results from STS101 SUMMIT Phase 3 efficacy trial in November 2022; NDA submission planned in Q1 2023 -

Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced positive safety, tolerability and efficacy results from its recent analysis of the Company's ongoing STS101 ASCEND Phase 3 open-label, long-term safety trial.

Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial

South San Francisco, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022, both virtually and in-person at the Lotte New York Palace Hotel.

Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 71.9% in Satsuma Pharmaceuticals (STSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Satsuma Pharmaceuticals (STSA) Have the Potential to Rally 72% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 90% in Satsuma Pharmaceuticals (STSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Satsuma Pharmaceuticals (STSA) Have the Potential to Rally 90% as Wall Street Analysts Expect?

- Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more than 1,400 subjects -

Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program

- More than 1,400 subjects randomized - -  Satsuma expects to announce topline SUMMIT trial results in Q4 2022 -

News for Satsuma Pharmaceuticals Inc Stock (STSA)